{"classes":[{"categories":[{"measurements":[{"comment":"Only one patient had data for this outcome measure so the standard deviation cannot be calculated","groupId":"OG000","spread":"NA","value":"8.702"}]}],"title":"Change in PDGFRA MAF"},{"categories":[{"measurements":[{"comment":"Only one patient had data for this outcome measure so the standard deviation cannot be calculated","groupId":"OG000","spread":"NA","value":"14.398"}]}],"title":"Change in KIT MAF"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Change of mutant allele fraction (MAF) summarizes the largest fold change. Change from baseline only displayed for patients with pre and post treatment MAF measurements. A positive number represents an increase in MAF. Data is only provided for patients that had both a baseline measurement and an end of treatment measurement.","dispersionType":"Standard Deviation","groups":[{"description":"Part 1 and Part 2: Patients enrolled in Part 1 and Part 2 at a starting dose of 300 or 400 mg QD were included in the Part1/Part 2 safety and efficacy analysis.\n\nPatients received avapritinib in continuous 28 day cycles until discontinuation.","id":"OG000","title":"Experimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QD"}],"paramType":"MEAN","populationDescription":"Patients enrolled in Part 1 or Part 2 with a starting dose of 300 or 400 mg QD","reportingStatus":"POSTED","timeFrame":"Baseline and End of treatment","title":"Change From Baseline in Levels of KIT and PDGFRα Mutant Allele Fractions in Peripheral Blood","type":"SECONDARY","unitOfMeasure":"fraction of total"}